Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors

A modular and controllable T cell therapy platform for acute myeloid leukemia

(2021) Mohamed-Reda Benmebarek et al.   LEUKEMIA

Mechanisms of resistance to CAR T cell therapy

(2019) Nirali N. Shah et al.   Nature Reviews Clinical Oncology

Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells

(2019) Mohamed-Reda Benmebarek et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

CHOPCHOP v3: expanding the CRISPR web toolbox beyond genome editing

(2019) Kornel Labun et al.   NUCLEIC ACIDS RESEARCH

PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer

(2019) Takahiro Kamada et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy

(2019) Stefan Stoiber et al.   Cells

Bispecific antibodies enable synthetic agonistic receptor-transduced T cells for tumor immunotherapy

(2019) Clara Helke Karches et al.   CLINICAL CANCER RESEARCH

The Immune Landscape of Cancer

(2018) Vésteinn Thorsson et al.   IMMUNITY

Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma

(2018) Catherine M. Bollard et al.   JOURNAL OF CLINICAL ONCOLOGY

Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication

(2018) Christopher C. Kloss et al.   MOLECULAR THERAPY

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

(2018) Jae H. Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System

(2018) Mauro P. Avanzi et al.   Cell Reports

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response

(2018) Peng Jiang et al.   NATURE MEDICINE

Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency

(2018) Judith Feucht et al.   NATURE MEDICINE

Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory

(2018) Sophie Viaud et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

(2017) Justin Eyquem et al.   NATURE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

CCR8+FOXp3+Tregcells as master drivers of immune regulation

(2017) Yiftah Barsheshet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Toxicities of chimeric antigen receptor T cells: recognition and management

(2016) Jennifer N. Brudno et al.   BLOOD

TGF  Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis

(2016) D. R. Principe et al.   CANCER RESEARCH

Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer

(2016) George Plitas et al.   IMMUNITY

Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient

(2016) Imran Siddiqui et al.   Journal for ImmunoTherapy of Cancer

Impact of a New Fusion Receptor on PD-1–Mediated Immunosuppression in Adoptive T Cell Therapy

(2015) Sebastian Kobold et al.   JNCI-Journal of the National Cancer Institute

Adoptive cell transfer as personalized immunotherapy for human cancer

(2015) S. A. Rosenberg et al.   SCIENCE

Impact of a New Fusion Receptor on PD-1–Mediated Immunosuppression in Adoptive T Cell Therapy

(2015) Sebastian Kobold et al.   JNCI-Journal of the National Cancer Institute

Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction

(2014) Christian A. Bauer et al.   JOURNAL OF CLINICAL INVESTIGATION

Differential Role of Th1 and Th2 Cytokines in Autotoxicity Driven by CD19-Specific Second-Generation Chimeric Antigen Receptor T Cells in a Mouse Model

(2014) E. J. Cheadle et al.   JOURNAL OF IMMUNOLOGY

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity

(2014) P. S. Adusumilli et al.   Science Translational Medicine

Tumor cell entry into the lymph node is controlled by CCL1 chemokine expressed by lymph node lymphatic sinuses

(2013) Suvendu Das et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Reassessing target antigens for adoptive T-cell therapy

(2013) Christian S Hinrichs et al.   NATURE BIOTECHNOLOGY

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

(2013) R. J. Brentjens et al.   Science Translational Medicine

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells

(2011) Barbara Molon et al.   JOURNAL OF EXPERIMENTAL MEDICINE

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

(2011) M. Kalos et al.   Science Translational Medicine

Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b

(2010) John A. Craddock et al.   JOURNAL OF IMMUNOTHERAPY

T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model

(2009) A. Di Stasi et al.   BLOOD

Efficient Human Hematopoietic Cell Transduction Using RD114- and GALV-Pseudotyped Retroviral Vectors Produced in Suspension and Serum-Free Media

(2009) Karim Ghani et al.   HUMAN GENE THERAPY